US FDA advisers to determine need for more studies of Vertex/CRISPR gene therapy
ReutersOCT 2023
FDA Approves Vertex's Non-Opioid Painkiller Journavx
Above: The painkillers fentanyl, tilidine and oxycodone on the counter in a pharmacy on Aug. 19, 2024. Image copyright: Monika Skolimowska/Picture Alliance via Getty Images
The Spin
Narrative A
For millions tormented by pain, Vertex's newly FDA-approved Journavx marks a revolutionary departure from traditional painkillers. Unlike older remedies, this breakthrough drug works by blocking specific sodium channels in peripheral nerves before pain signals can reach the brain. This offers opioid-level relief without addiction risks, making it the first new class of pain medication in over 20 years.
Narrative B
While Vertex's VX-548 has been hailed as revolutionary, early data suggests a sobering reality. The drug failed to outperform even low-dose Vicodin in surgical pain, and recent trials for chronic pain showed it working no better than a placebo. Though safer than opioids, its pain-relieving effects are slow to kick in, taking up to eight hours post-surgery. For millions seeking relief, this "breakthrough" may be more smart marketing than medicine.